ABSTRACT
Mycobactin biosynthesis in
Mycobacterium tuberculosis
facilitates iron acquisition, which is required for growth and virulence. The mycobactin biosynthesis inhibitor salicyl-AMS [5′-
O
-(
N
-salicylsulfamoyl)adenosine] inhibits
M. tuberculosis
growth
in vitro
under iron-limited conditions. Here, we conducted a single-dose pharmacokinetic study and a monotherapy study of salicyl-AMS with mice. Intraperitoneal injection yielded much better pharmacokinetic parameter values than oral administration did. Monotherapy of salicyl-AMS at 5.6 or 16.7 mg/kg significantly inhibited
M. tuberculosis
growth in the mouse lung, providing the first
in vivo
proof of concept for this novel antibacterial strategy.
摘要
结核分枝杆菌中
分枝杆菌素的
生物合成
结核分枝杆菌
促进
铁的获得,而
铁是生长和毒力所必需的。分枝菌素
生物合成
抑制剂水杨酰-
AMS [5′-
O
-(
N
水杨酰-
AMS[5′- O -(N
结核杆菌
生长
体外
在
铁限制条件下抑制结核杆菌的体外生长。在此,我们对小鼠进行了
水杨酰-
AMS 的单剂量药代动力学研究和单药治疗研究。腹腔注射获得的药代动力学参数值远高于口服给药。5.6 或 16.7 毫克/千克剂量的
水杨酰-
AMS 单药疗法可显著抑制
结核杆菌
在小鼠肺部的生长,首次在
体内
证明了这种新型抗菌策略的概念。